bioRxiv · 10.1101/2021.01.05.425414
LiquidCNA: tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations
Abstract
Cell-free DNA (cfDNA) measured via liquid biopsies provides a way for minimally-invasive monitoring of tumour evolutionary dynamics during therapy. Here we present liquidCNA, a method to track subclonal evolution from longitudinally collected cfDNA samples based on somatic copy number alterations (SCNAs). LiquidCNA utilises SCNA profiles derived through cost-effective low-pass whole genome sequencing to automatically and simultaneously genotype and quantify the size of the dominant subclone without requiring prior knowledge of the genetic identity of the emerging clone. We demonstrate the accuracy of liquidCNA in synthetically generated sample sets and in vitro and in silico mixtures of cancer cell lines. Application in vivo in patients with metastatic lung cancer reveals the progressive emergence of a novel tumour sub-population. LiquidCNA is straightforward to use, computationally inexpensive and enables continuous monitoring of subclonal evolution to understand and control therapy-induced resistance.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Lakatos, E., Hockings, H., Mossner, M., Lockley, M., Graham, T. A.. 2021-01-06. LiquidCNA: tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations. https://doi.org/10.1101/2021.01.05.425414
Cite the original work for its findings. Save a collection to share your selection of sources.